Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 629

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 629
---
684) 
     (29,455)

    Increase for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date 
     14,800  
     1,383 

    TOTAL ADJUSTMENTS 
    $(127,936) 
    $(104,019)

Fair
value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined
by reference to a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used
to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and
with an estimated expected life using the simplified method, and in all cases based on volatility and risk free rates determined as of
the revaluation date based on the expected life period and based on an expected dividend rate of 0%. For additional information on the
assumptions used to calculate the valuation of the awards, see Note 5 to our consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 13, 2025.

88

Narrative
Disclosure to Pay Versus Performance Table

Relationship
Between Financial Performance Measures

The
graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs,
with our cumulative TSR for the fiscal years ended December 31, 2022, 2023 and 2024.

TSR
amounts reported in the graph assume an initial fixed investment of $100. We do not pay dividends.

The
graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our remaining NEOs,
with our net loss for the fiscal years ended December 31, 2022, 2023 and 2024.

Director
Compensation

The
following table provides certain information concerning the compensation for services rendered in all capacities by each non-employee
director serving on our Board during the year ended December 31, 2024, other than Mr. Meckler, our Chief Executive Officer who did not
receive additional compensation for their service as a director and whose compensation is set forth in the Summary Compensation Table
under the section entitled Executive Compensation above. Dr. Newman, our